Ocular Therapeutix (OCUL) Consolidated Net Income: 2013-2025

Historic Consolidated Net Income for Ocular Therapeutix (OCUL) over the last 13 years, with Sep 2025 value amounting to -$68.0 million.

  • Ocular Therapeutix's Consolidated Net Income fell 56.01% to -$68.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$247.3 million, marking a year-over-year decrease of 78.13%. This contributed to the annual value of -$165.1 million for FY2024, which is 83.96% down from last year.
  • Per Ocular Therapeutix's latest filing, its Consolidated Net Income stood at -$68.0 million for Q3 2025, which was down 1.14% from -$67.2 million recorded in Q2 2025.
  • In the past 5 years, Ocular Therapeutix's Consolidated Net Income registered a high of -$19.5 million during Q1 2022, and its lowest value of -$68.0 million during Q3 2025.
  • For the 3-year period, Ocular Therapeutix's Consolidated Net Income averaged around -$41.2 million, with its median value being -$40.8 million (2024).
  • Its Consolidated Net Income has fluctuated over the past 5 years, first climbed by 10.95% in 2022, then crashed by 115.51% in 2024.
  • Ocular Therapeutix's Consolidated Net Income (Quarterly) stood at -$19.7 million in 2021, then fell by 5.38% to -$20.8 million in 2022, then fell by 9.42% to -$22.7 million in 2023, then slumped by 115.51% to -$49.0 million in 2024, then plummeted by 56.01% to -$68.0 million in 2025.
  • Its Consolidated Net Income stands at -$68.0 million for Q3 2025, versus -$67.2 million for Q2 2025 and -$63.1 million for Q1 2025.